Amaryl 4 mg tablets are used for the treatment of type 2 diabetes mellitus (as monotherapy or as part of combination therapy with metformin or insulin) when adequate glycemic control cannot be achieved through diet, physical exercise, or weight reduction alone.
Each tablet contains:
Active ingredient: 4 mg of glimepiride
Excipients: lactose monohydrate, sodium carboxymethyl starch (type A), povidone 25000 (E1201), microcrystalline cellulose (E460), magnesium stearate (E470), ferric oxide yellow (E172), indigo carmine aluminum lake (E132).
Type 2 diabetes mellitus (non–insulin-dependent), as monotherapy or in combination with metformin or insulin, when adequate glycemic control cannot be achieved through diet, physical exercise, or weight reduction alone.
Oral use only.Effective diabetes treatment relies on proper diet, regular physical activity, and frequent monitoring of blood and urine glucose levels. Dietary noncompliance cannot be compensated by tablets or insulin.
Initial dose and dose titration:
Glimepiride dosage is determined based on blood and urine glucose test results.
Starting dose: 1 mg glimepiride per day. If effective metabolic control is achieved, the dose should be maintained.
Tablets of varying strengths are available for different dosage regimens.
If needed, the daily dose may be gradually increased in 1- to 2-week intervals based on glucose monitoring using the following steps: 1 mg → 2 mg → 3 mg → 4 mg → 6 mg per day.
The maximum recommended daily dose is 6 mg.
The timing and frequency of the daily dose are determined by the physician, based on the patient's lifestyle. Generally, a single daily dose is taken immediately before or with a substantial breakfast. If a dose is missed, it should be taken with the next meal. Do not double the dose to compensate for a missed one.
Amaryl tablets should be swallowed whole with a sufficient amount of liquid (approximately half a glass of water).
It is essential not to skip meals after taking Amaryl.
Use in combination with metformin:
In patients who are inadequately controlled on metformin alone, glimepiride may be added.
While maintaining the metformin dose, glimepiride is initiated at a low dose and gradually titrated up to a maximum daily dose of6 mg, depending on glycemic response.
Combined therapy must be conducted under close medical supervision.
Use in combination with insulin:
In cases where maximum doses of glimepiride or its combination with the maximum dose of metformin are insufficient to control blood glucose levels, glimepiride may be used together with insulin.
The last prescribed dose of glimepiride remains unchanged, and insulin therapy is initiated at a low dose, titrated gradually based on glucose levels.
This combination therapy requires careful medical supervision.
Long-term glycemic control with this combination may reduce insulin requirements by up to 40%.
Glimepiride should not be used in the following cases:
Known hypersensitivity to glimepiride, any of the excipients, other sulfonylureas, or sulfonamides (due to risk of hypersensitivity reactions)
Insulin-dependent (type 1) diabetes mellitus
Diabetic ketoacidosis, pre-coma, or coma
Severe liver dysfunction
Severe renal impairment (including patients undergoing hemodialysis)
Pregnancy and lactation
Store at temperatures not exceeding 25°C.
Keep out of reach of children.
